CC
CERE

Casdin Capital’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Casdin Capital’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-80,000
Closed -$2.26M – 49
2022
Q3 		$2.26M Buy
+80,000
New +$2.38M 0.15% 33

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Casdin Capital's CERE Position: Q4 2022 in Review

Casdin Capital sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2022, closing a stake of 80,000 shares — an estimated $2.26M sold.

Casdin Capital first reported a position in CERE in Q3 2022 and held it in 1 quarter. The position peaked at $2.26M in Q3 2022. 125 funds tracked by Wall St. Rank hold CERE as of Q4 2022.

  • Casdin Capital reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Casdin Capital sold 80,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $2.26M.
  • Casdin Capital first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Casdin Capital's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $2.26M in Q3 2022.
  • 125 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Casdin Capital's 13F filing for Q4 2022, filed 14 Feb 2023.